Premium
Intrauterine administration of autologous peripheral blood mononuclear cells ( PBMC s) activated by HCG improves the implantation and pregnancy rates in patients with repeated implantation failure: a prospective randomized study
Author(s) -
Yu Nan,
Zhang Bo,
Xu Mei,
Wang Sheng,
Liu Rong,
Wu Jianli,
Yang Jing,
Feng Ling
Publication year - 2016
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12542
Subject(s) - peripheral blood mononuclear cell , medicine , embryo transfer , implantation failure , pregnancy , miscarriage , andrology , in vitro fertilisation , embryo , prospective cohort study , infertility , in vitro , biology , biochemistry , genetics , microbiology and biotechnology
Problem Intrauterine administration of autologous peripheral blood mononuclear cells ( PBMC s) activated by HCG in vitro was reported to improve implantation rates in patients with repeated failure of IVF ‐ ET (in vitro fertilization–embryo transfer). In this article, the value of intrauterine administration of PBMC s before embryo transfer and its optimal cell culture method will be investigated. Method of study Patients who had not experienced successful pregnancy despite three or more IVF ‐ ET sessions were enrolled in this study (n=240, 240 cycles). PBMC s were obtained from patients themselves and were cultured with HCG for 24 hours. Twenty‐four hours later, PBMC s were then administered to the intrauterine cavity of that patient from the study group (n=93, 93 cycles). The control group (n=105, 105 cycles) underwent ET without intrauterine administration. Results Clinical pregnancy rate, implantation rate, and miscarriage rate in the PBMC ‐treated group (46.24% and 23.66%, n=43 and 22, respectively) were significantly higher than those in the non‐treated group (20.95% and 11.43%, P <.05; n=22 and 12, respectively). Conclusion These findings indicate that intrauterine administration of autologous PBMC activated by HCG in vitro effectively improves embryo implantation in patients with three or more IVF failures.